低價藥治MS有效

挪威與瑞典最新一項發表於《新英格蘭醫學期刊》（NEJM）的隨機雙盲臨床試驗顯示，低成本的B細胞耗竭療法利妥昔單抗（rituximab），在新診斷的復發型多發性硬化症（relapsing multiple sclerosis, RMS）患者中，療效與安全性均可與目前常用的高價標靶藥物ocrelizumab相當。這項名為OVERLORD-MS的研究，是全球首個直接比較兩種抗CD20療法於早期多發性硬化症患者中的隨機、雙盲、頭對頭試驗，結果不僅對MS臨床治療策略具有指標性意義，也可能重新改變各國對高效能神經免疫藥物的給付與採購思維。

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine has found that rituximab, a lower-cost B-cell-depleting therapy, performs as well as ocrelizumab in patients with newly diagnosed relapsing multiple sclerosis, offering what researchers say could be a major breakthrough for treatment access and healthcare affordability in MS.

The study, known as OVERLORD-MS, is the first randomized, double-blind, head-to-head trial to directly compare rituximab and ocrelizumab in early relapsing MS. Patients across Norway and Sweden were followed for 30 months using MRI scans and clinical assessments. Researchers reported comparable efficacy and safety between the two therapies, a finding that could have significant implications for treatment protocols, reimbursement policy and the economics of high-efficacy MS care.

多發性硬化症是一種中樞神經系統慢性自體免疫疾病，主要影響腦部與脊髓，病程常伴隨反覆發作、神經功能損傷與長期失能風險。近年來，神經科治療策略逐漸從「逐步升級」轉向「早期使用高效療法」，亦即在疾病初期即積極壓制免疫發炎與神經損傷，以降低未來復發頻率、延緩腦部病灶進展並保留神經功能。不過，這類高效藥物通常價格高昂，使得即便在高收入國家，支付端也承受龐大財務壓力；在中低收入地區，患者更常因價格門檻而無法及早接受最佳治療。

The result matters because early use of highly effective therapy is increasingly seen as one of the most important determinants of long-term outcomes in multiple sclerosis. In recent years, neurologists have moved away from a gradual escalation approach toward earlier intervention with stronger disease-modifying treatments in an effort to suppress inflammatory activity before irreversible neurological damage accumulates. But that strategy comes with a cost problem: many of the most effective MS therapies remain expensive, limiting access for patients and straining public and private healthcare budgets alike.

OVERLORD-MS試驗正是在這樣的背景下受到高度關注。研究納入來自挪威與瑞典、剛被診斷為復發型MS的患者，並在30個月內透過磁振造影（MRI）與臨床評估持續追蹤兩種藥物的治療效果與安全性。結果顯示，利妥昔單抗與ocrelizumab在控制疾病活動度方面表現相當，未見明顯療效差距，安全性概況也具可比性。研究團隊指出，這項結果為利妥昔單抗在MS領域的使用提供了迄今最具說服力的高等級臨床證據。

從機轉來看，利妥昔單抗與ocrelizumab同屬抗CD20單株抗體，皆以耗竭B細胞為核心作用方式。B細胞近年被視為MS發病機制中的關鍵角色之一，不僅參與抗體生成，也牽涉抗原呈現、發炎細胞激素釋放，以及中樞神經系統內慢性免疫活化。透過清除特定B細胞族群，抗CD20療法已成為近年MS高效治療的重要支柱。ocrelizumab作為專為MS開發並獲多國核准的治療藥物，在全球市場占有重要地位；相較之下，利妥昔單抗原本主要用於淋巴瘤與自體免疫疾病，雖然在北歐等地早已有相當多MS臨床使用經驗，但過去較缺乏直接與ocrelizumab正面比較的隨機對照證據。

That is where rituximab enters the picture. Both rituximab and ocrelizumab target CD20-positive B cells, which are now understood to play a central role in MS pathogenesis through antibody production, antigen presentation and inflammatory signaling. Ocrelizumab was specifically developed and approved for MS and has become one of the leading anti-CD20 therapies in the market. Rituximab, by contrast, was originally developed for lymphoma and autoimmune diseases and has often been used off-label in MS, particularly in Nordic countries. Although real-world evidence has long suggested strong performance for rituximab in MS, the absence of direct randomized evidence against ocrelizumab left an important gap in the evidence base. OVERLORD-MS is the first trial to close that gap at a high evidentiary standard.

這也是OVERLORD-MS研究最具政策含義之處。研究主持團隊之一、挪威卑爾根大學教授暨Haukeland大學醫院神經科醫師Øivind Torkildsen指出，該試驗顯示「高效MS治療可以在不犧牲患者療效的前提下，以大幅更低的成本提供」。這項結論對各國健保體系、公共採購與醫療資源配置尤其重要。若低價的利妥昔單抗在臨床成效上可與高價創新藥匹敵，意味著醫療體系有機會以更低成本擴大高效治療覆蓋率，讓更多患者在疾病早期就接受足夠強度的治療，而不是因價格限制而延後或退而求其次。

According to the study team, the findings show that high-efficacy MS care can be delivered at substantially lower cost without compromising patient outcomes. Øivind Torkildsen, professor at the University of Bergen and consultant neurologist at Haukeland University Hospital, said the study demonstrates that effective treatment does not necessarily have to depend on premium-priced branded therapies. That conclusion could resonate well beyond Scandinavia. If payers and guideline bodies accept rituximab as a clinically equivalent option in newly diagnosed relapsing MS, healthcare systems may be able to expand access to high-efficacy therapy while easing budget pressure.

The implications may be particularly significant in lower-income settings, where many patients still do not have access to modern MS drugs because of cost barriers. Torkildsen said the findings suggest that effective treatment could become available to far more people if lower-cost options such as rituximab are backed by robust trial evidence. In practical terms, the study could strengthen the case for including rituximab more formally in treatment pathways, national reimbursement schemes and essential access strategies in countries where ocrelizumab remains unaffordable for large parts of the population.

對全球MS治療公平性而言，這項研究的潛在衝擊可能更為深遠。研究團隊直言，在許多地區，患者至今仍因藥價過高而無法取得現代MS療法；若利妥昔單抗的證據基礎進一步被國際指南、給付政策與臨床實務納入，未來可能成為推動MS高效治療普及化的重要槓桿。尤其在中低收入國家，醫療體系對藥價敏感度高，若能以較低成本導入具相當療效的B細胞療法，將有助縮小不同國家間在神經免疫疾病照護上的落差。

The trial also adds a scientific dimension beyond comparative drug performance. OVERLORD-MS contributes biomaterial and mechanistic insights to the broader EBV-MS research initiative, which is examining the role of Epstein-Barr virus in the development and progression of multiple sclerosis. That connection is important because B cells are the main reservoir for latent EBV infection, and both rituximab and ocrelizumab deplete B cells. Researchers are now using biomaterial collected during the trial to explore how B-cell depletion affects EBV-related immune mechanisms in MS. This gives the study a translational relevance that extends beyond treatment choice into disease biology, potentially helping researchers better understand the viral and immunological drivers of MS itself.

值得注意的是，這項試驗的價值不僅限於藥物比較本身，也與多發性硬化症病因研究的前沿方向相互連結。OVERLORD-MS同時納入了與EBV-MS研究計畫相關的生物樣本與機轉探索。近年愈來愈多研究認為，愛潑斯坦—巴爾病毒（Epstein-Barr virus, EBV）與MS發病之間存在高度關聯，而B細胞正是EBV潛伏感染的重要宿主。由於rituximab與ocrelizumab都會耗竭B細胞，研究團隊現正利用試驗中收集的生物材料，進一步分析B細胞耗竭對EBV相關免疫機制的影響，試圖釐清EBV在MS發生、復發與病程惡化中的角色。這使OVERLORD-MS不只是治療試驗，也成為串聯臨床療效與疾病機轉研究的重要平台。

The study also stands out as an example of the policy value of publicly funded academic trials. OVERLORD-MS was coordinated by Neuro-SysMed and funded through Norway’s national clinical trials program KLINBEFORSK, rather than being driven by a pharmaceutical company’s commercial agenda. That matters in an environment where many pivotal drug studies are designed primarily to support product approvals or market positioning. Independent head-to-head trials such as this one can instead answer questions that are directly relevant to health systems: whether a cheaper existing therapy can deliver the same patient benefit as a more expensive branded option, and whether scarce healthcare resources can be deployed more efficiently without compromising care quality.

從研究治理與醫療政策角度來看，OVERLORD-MS也凸顯「獨立學術臨床試驗」的重要性。該研究由挪威Neuro-SysMed協調，並透過挪威國家臨床試驗計畫KLINBEFORSK提供公共資金支持。相較於由藥廠主導、以新藥開發與上市為目標的臨床試驗，這類公共資助研究更有可能直接回應醫療體系在成本效益、用藥可近性與給付決策上的實際問題。對於近年醫療財務壓力升高、藥價爭議頻傳的歐洲各國而言，這類研究可望成為未來價值型醫療與藥品政策調整的重要依據。

For the MS field, the study reinforces a broader shift in thinking. The next wave of treatment progress may not come solely from entirely new therapies, but also from better evidence about how to use existing therapies more effectively, more affordably and more equitably. If the OVERLORD-MS findings influence clinical practice and reimbursement frameworks, rituximab could move from being an off-label workaround in some health systems to a more formally recognized cornerstone of high-efficacy MS treatment.

整體而言，OVERLORD-MS試驗傳遞出一項明確訊號：在多發性硬化症這類需要長期管理、且愈早控制愈能改善預後的疾病領域，治療創新不一定只意味著更昂貴的新藥，也可能來自於以高品質臨床證據重新評估既有藥物的角色。如果低成本rituximab能在更廣泛的臨床與政策層面被接受，MS治療未來的競爭焦點將不只是藥物創新本身，而是如何在療效、成本、可近性與健康公平之間取得更具系統性的平衡。

That would make the study important not only as a clinical comparison, but as a test case for a larger question facing healthcare systems globally: how to expand access to advanced treatment while containing costs. In multiple sclerosis, where long-term disability prevention depends heavily on early and sustained disease control, that question is not only financial. It is central to patient outcomes, health equity and the future sustainability of neurological care.